BRAF and colorectal carcinoma: Therefore, BRAF mutation testing in CRC is often no longer carried out as an isolated individual test but integrated into the parallel detection of other molecular alterations such as KRAS and NRAS. The sensitivity of NGS-based methods is generally very high (approximately 1% detection limit), but hampered by artifacts occurring during formalin fixation.